Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EBT: 2012-2025

Historic EBT for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to -$23.1 million.

  • Ptc Therapeutics' EBT rose 76.45% to -$23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.3 million, marking a year-over-year increase of 198.29%. This contributed to the annual value of -$598.8 million for FY2024, which is 23.69% up from last year.
  • Per Ptc Therapeutics' latest filing, its EBT stood at -$23.1 million for Q3 2025, which was up 67.53% from -$71.1 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' EBT registered a high of $929.8 million during Q1 2025, and its lowest value of -$330.4 million during Q4 2024.
  • Its 3-year average for EBT is -$49.8 million, with a median of -$98.0 million in 2024.
  • Its EBT has fluctuated over the past 5 years, first crashed by 181.96% in 2021, then soared by 1,197.84% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' EBT stood at -$138.6 million in 2021, then plummeted by 39.48% to -$193.3 million in 2022, then dropped by 27.08% to -$245.7 million in 2023, then tumbled by 34.48% to -$330.4 million in 2024, then soared by 76.45% to -$23.1 million in 2025.
  • Its EBT stands at -$23.1 million for Q3 2025, versus -$71.1 million for Q2 2025 and $929.8 million for Q1 2025.